A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

NCT06947941 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

325

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease
Psychosis

Interventions

DRUG: KarXT
DRUG: KarX-EC
DRUG: KarXT + KarX-EC Arm Matching Placebo

Sponsor

Bristol-Myers Squibb